Molecular Therapy — Methods & Clinical Development · 2018 · 20 citations · 41 references
MedicineNeurobiologyNeuroscienceDrug DeliveryGene DeliveryGene TherapyGene Delivery VectorsIn Vivo Gene DeliveryIn Vivo Gene TherapyNeurological Gene TherapySafety Of Gene TherapyTissue TargetingFunctional CorrectionGene Delivery To The BrainGene-targeted TherapyNeurological DysfunctionNeurological EffectsPreclinical Disease StagesSafe Intravenous InjectionToxicity Of Gene Vectors
at different doses. The treatments led to rapid and persistent restoration of IDS activity and the reduction of glycosaminoglycans (GAG) throughout the CNS and somatic tissues in all cohorts. Importantly, the vector treatment at up to age 6 months improved behavior performance in the Morris water maze and normalized the survival. Notably, vector treatment at age 9 months also resulted in persistent rIDS expression and GAG clearance in MPS II mice, and the majority of these animals survived within the normal range of lifespan. Notably, the vector delivery did not result in any observable adverse events or detectable systemic toxicity in any treated animal groups. We believe that we have developed a safe and effective gene therapy for treating MPS II, which led to recent IND approval for a phase 1/2 clinical trial in MPS II patients, further supporting the extended potential of the demonstrated systemic rAAV9 gene delivery platform for broad disease targets.
41
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust, Emily Nurre, Chrystal L. Montgomery et al. · Nature Biotechnology · 2008 · 1.4K citations · Full text